Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

Autor: Shigenori Kadowaki, Hiroko Hasegawa, Seiichiro Mitani, Masashi Ando, Yasushi Yatabe, Hiroya Taniguchi, Toshiki Masuishi, Kei Muro, Azusa Komori, Takashi Ura, Yukiya Narita
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
Organoplatinum Compounds
genetic structures
Colorectal cancer
medicine.medical_treatment
Leucovorin
Cetuximab
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
integumentary system
biology
Panitumumab
Antibodies
Monoclonal
General Medicine
Middle Aged
Bevacizumab
ErbB Receptors
Treatment Outcome
030220 oncology & carcinogenesis
Female
Fluorouracil
Antibody
Colorectal Neoplasms
medicine.drug
Adult
medicine.medical_specialty
Disease-Free Survival
03 medical and health sciences
Growth factor receptor
Internal medicine
medicine
Humans
Aged
Retrospective Studies
Chemotherapy
business.industry
Retrospective cohort study
medicine.disease
eye diseases
Clinical trial
030104 developmental biology
biology.protein
Camptothecin
sense organs
business
Zdroj: Oncology. 92:205-212
ISSN: 1423-0232
0030-2414
Popis: Objective: Anti-epidermal growth factor receptor (EGFR) antibodies and bevacizumab are commonly used, sequentially, as palliative chemotherapies for patients with metastatic colorectal cancer. However, little is known about the efficacy of second-line treatments containing bevacizumab after first-line treatment with an anti-EGFR antibody. Methods: We retrospectively reviewed 128 patients who received second-line bevacizumab-containing chemotherapy and evaluated the effect of prior use of anti-EGFR antibody on the efficacy of the second-line treatment. Results: As first-line treatments, 35 of these patients received only cytotoxic chemotherapy (cohort A), 58 received bevacizumab-containing chemotherapy (cohort B), and 35 received anti-EGFR-containing chemotherapy (cohort C). The median progression-free survival (PFS) with the second-line bevacizumab-containing therapy was 8.3 months in cohort C, 6.9 months in cohort A (hazard ratio [HR], 1.43; 95% confidence interval [CI], 0.83-2.51), and 5.6 months in cohort B (HR, 1.95; 95% CI, 1.18-3.22). Multivariate analysis showed that PFS in cohort C was the same as that in cohort A, but better than that in cohort B. The overall response rate in cohort C (25.7%) was also similar to that in cohort A (20.0%), but better than that in cohort B (10.3%). Conclusions: Prior use of anti-EGFR antibody did not adversely affect the efficacy of subsequent bevacizumab-containing chemotherapy.
Databáze: OpenAIRE
Externí odkaz: